Jordi Bove Badell I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases. Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca Email Jordi Bove Badell Email Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.
I received a Pharmacy degree from the University of Barcelona in 1998. In 2003, I got a PhD in Pharmacy (Neurobiology) with cum laude distinction from the same university at the Experimental Neurology Laboratory, Neurological Service of Hospital Clínic de Barcelona-IDIBAPS (Dr. C. Marin/Prof. E. Tolosa). My doctoral thesis shed light on the mechanism of levodopa-induced motor fluctuations in Parkinson's disease. I later joined the laboratory of Dr. Serge Przedborski at Columbia University (New York, USA) as a post-doctoral researcher (2003-2005), working on animal modeling and the role of alpha-synuclein in Parkinson's disease. In 2006 I co-founded the Neurodegenerative Diseases Research Group at Vall d’Hebron Research Institute (VHIR) in the Vall d’Hebron Hospital Campus (Barcelona) with its leader Dr. Miquel Vila. In 2011, I obtained a position as a Miguel Servet Investigator (Instituto de Salud Carlos III, Spain) as a Researcher in the National System of Health, and since then I am one of the principal investigators of the group. The research that I am leading is aimed to elucidate the mechanism of neuron cell death and to determine new therapeutic targets to develop neuroprotective strategies for Parkinson’s disease and other neurodegenerative diseases. I am also interested in establishing presymptomatic biomarkers of Parkinson´s disease. I am currently focused on the role of the adaptive immune system in Parkinson’s disease. Our latest published study suggests that a cytotoxic attack induced by CD8 T lymphocytes initiates the disease.
Projects Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment IP: Jordi Bove Badell Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 121500 Reference: CP11/00229 Duration: 01/01/2012 - 30/06/2015 Mecanismos de propagación y progresión de la enfermedad de Parkinson: rol de los cuerpos de Lewy IP: Miquel Vila Bover Collaborators: Jordi Bove Badell Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 35000 Reference: SAF2009-06575-E Duration: 05/03/2010 - 04/03/2011 NLF-siRNA como tratamiento del Parkinson en modelos experimentales de la enfermedad IP: Miquel Vila Bover Collaborators: Jordi Bove Badell Funding agency: CENTRO PARA EL DESARROLLO TÉCNICO INDUSTRIAL (CDTI Funding: 177880 Reference: CENIT-2010-02 Duration: 01/01/2011 - 31/12/2013 Grup de Recerca en Malalties Neurodegeneratives IP: Miquel Vila Bover Collaborators: Marta Martínez Vicente, Jordi Bove Badell, Annabelle Parent Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 41600 Reference: 2009 SGR 664 Duration: 01/01/2010 - 30/04/2014 Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Next page › Last page »
